Introduction
Drug candidates discovered from in vitro screening systems sometimes show no therapeutic effects in in vivo models using mice, rats, rabbits and so on as a host animal. There are gaps between in vitro and in vivo assay systems due to the following reasons: membrane permeability of drugs, metabolism of drugs and involvement of host immune systems; therefore, the introduction of in vivo assay systems at the early stage of screening programs is effective to fill the gaps, although in vivo screening is a time-and costconsuming method and is therefore unrealistic. On the other hand, there is increased public concern towards eradicating animal experiments from the perspective of animal protection. Furthermore, the implementation of animal experiments is stringently regulated worldwide. Particularly in the European Union, widespread administration of all new drug candidates to healthy animals was forbidden in 1998.
To overcome these problems, researchers have focused on non-mammalian animals such as Zebrafish (1) , Caenorhabditis elegans (2), Drosophila melanogaster (3) , and silkworms (4) (5) (6) (7) (8) as alternative hosts for in vivo screening systems. On the discovery of antibiotics active against methicillin-resistant Staphylococcus aureus (MRSA) from microbial metabolites, we established an in vivo-mimic MRSA infection assay using silkworm larvae as a host animal and started to apply this assay to the primary screening for new anti-MRSA antibiotics of microbial origin. In this assay, MRSA-infected silkworm larvae die within 3 day. If drug candidates are effective, silkworm larvae can survive. We predicted that drug candidates discovered by the silkworm infection assay would have higher potential effectiveness in in vivo systems than those discovered by in vitro assays using paper disks. During the course of this screening program, nosokomycins A to D (Figure 1 ) were isolated as potent antibiotics from the culture broth of Streptomyces cyslabdanicas K04-0144 (8, 9) . In this study, in vitro and in vivo anti-MRSA activities of nosokomycins are described.
Materials and Methods

Materials
Nosokomycins A to D were purified from a culture broth of Streptomyces cyslabdanicas K04-0144, as reported (8, 9) . Vancomycin and linezolid were obtained from Wako Pure Chemical Industries (Osaka, Japan). Arbekacin was purchased from Meiji Seika Pharma (Tokyo, Japan). Unless otherwise stated, all other reagents were reagent-grade commercial products.
Animals
Fertilized silkworm eggs, Bombyx mori (Hu•Yo × Tukuba•Ne), were purchased from Ehime Sansyu (Ehime, Japan) and fed artificial food (Silkmate 2S; Nihon Nosan Kogyo; Silkmate; Katakura Industries, Tokyo, Japan) until the fourth-instar larval stage. Female ICR mice (18-20 g, 4 weeks old) were obtained from Charles River (Kanagawa, Japan).
Microorganisms
Fifty-four MRSA strains, including N315 IR94, N315 IR94 HR-1 and K24, were clinically collected in Japan (10) 
Preparation of microorganism suspension
All microorganisms except Staphylococcus sp. were grown overnight at 37°C in Trypticase soy broth (TSB; BBL Microbiology Systems, Cockeysville, MD, USA). The cultures were diluted with the same broth and adjusted to an optical density at 600 nm of 0.3 (about 10 8 CFU/mL). Staphylococcus sp. was grown overnight at 37°C on Mueller-Hinton agar (MHA; Becton Dickinson, San Jose, CA, USA) containing chocolate horse blood at a final concentration of 10% (v/v), and the colonies were then suspended in a sufficient amount of TSB to make a cell suspension with an optical density at 600 nm of 0.3.
Determination of minimum inhibitory concentration (MIC) values
MICs of nosokomycins and authentic antibiotics (vancomycin, arbekacin and linezolid) were measured according to the agar dilution method recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (11) . For the MIC assay, MHA was used as a medium for test microorganisms except Staphylococcus sp., and MHA supplemented with 5% horse blood was used for Staphylococcus sp. The bacterial suspensions were then diluted 100-fold with the same fresh broth (about 10 6 CFU/mL). One loopful (5 μL) of the cell suspension was inoculated onto agar plates containing various concentrations of nosokomycin and authentic antibiotics using an inoculator (Microplanter; Sakuma Seisakusho, Tokyo, Japan). Growth of bacteria was evaluated after 18-h incubation at 37°C. The MIC was defined as the lowest drug concentration that showed 95% growth inhibition of bacteria.
Population analysis of nosokomycins against clinically isolated MRSA
Resistant subpopulations of 54 clinically isolated MRSA strains (population analysis) were analyzed by the established method (12, 13) . MRSA culture suspension (50 μL, overnight MRSA culture diluted 
In vivo MRSA infection assay using mice
The in vivo effect of nosokomycin A on systemic MRSA infection was studied using female ICR mice (18-20 g, 4 weeks old) (10) . S. aureus 92-1191 (highly drug-resistant MRSA; MIC value of methicillin: > 100 μg/mL) was routinely grown in brain-heart infusion broth (BHI; Becton Dickinson) at 35°C overnight with agitation on a rotary shaker at 45 rpm. Mice were intraperitoneally infected with 1 × 10 9 CFU of MRSA 92-1191 in 0.1 mL phosphate-buffered saline (pH 7.4) containing 0.01% (w/v) gelatin and 10% (w/v) mucin from swine stomach (Wako Pure Chemical Industries). One hour later, nosokomycin A suspended in saline was subcutaneously injected into the back of mice (s.c.) or intravenously administrated (i.v.) at doses of 3.13, 6.25, 12.5 and 25 mg/kg (five mice per each dose), and the survival rates were recorded for five days. Vancomycin was evaluated under the same conditions.
Results
Antibacterial activity of nosokomycins A to D against pathogenic microorganisms
The MIC values of nosokomycins against various pathogenic bacteria including MRSA are shown in Table  1 . Under the same conditions, clinically used antibacterial agents, vancomycin, arbekacin and linezolid, were tested (Table 1) . Nosokomycins were found to be as active to an optical density at 550 nm of 0.3) was spread on MHA plates containing various concentrations of nosokomycins or authentic antibiotics. The plates were incubated at 37°C at 48-h and the number of growth strains was counted.
In vivo-mimic MRSA infection assay using silkworm larvae
An in vivo-mimic MRSA infection assay using silkworm larvae was carried out by the established method with some modification (7, 8) . Hatched silkworm larvae were raised by feeding an artificial diet containing antibiotics (Silk Mate 2S, Nihon Nosan Kogyo, Kanagawa, Japan) in an incubator at 27°C until the fourth molting stage. On the first day of fifth-instar larvae, silkworms were fed an antibiotic-free artificial diet (Silk Mate, Katakura Industries, Saitama, Japan) for 24 h. On the second day, MRSA K-24 (2.5 × 10 7 CFU in 50 μL, LB medium containing 10% NaCl) was injected into the hemolymph through the dorsal surface of the silkworms using a disposable 1-mL syringe with a 27G needle (TERUMO, Tokyo, Japan). Immediately (within one hour) after MRSA K-24 injection, a test sample (50 μL in 10% DMSO) was injected into the hemolymph. When they were maintained in an incubator at 27°C, all the MRSAinfected silkworm larvae without a sample died within 3 days. Under these conditions, when vancomycin (50 μg per larva) was injected, all silkworms survived, even on day 3. 
Population analysis of nosokomycins A to D
Since nosokomycins were found to show potent activity against most Gram-positive bacteria, anti-MRSA activity was investigated in more detail by population analysis using 54 clinically isolated MRSA strains. As shown in Figure 2 , the growth of all 54 MRSA strains (100%) was inhibited by 0.25 μg/mL nosokomycin B, while the growth of 55%, 22%, and 18% MRSA strains was inhibited by 0.25 μg/mL nosokomycins A, D and C, respectively. At 0.5-2 μg/mL, nosokomycins A, D, and C also showed 100% inhibition of those MRSA strains. From this population analysis, nosokomycin B showed the most potent anti-MRSA activity, followed by nosokomycins A, D, and C. Arbekacin was as potent as nosokomycin D, and vancomycin was as potent as nosokomycin C. Linezolide was the least among the drugs tested in this analysis.
Therapeutic efficacy of nosokomycin A in MRSAinfected silkworm larvae
Nosokomycins were evaluated in the in vivo-mimic MRSA infection assay using silkworm larvae. As shown in Figure 3 , when nosokomycin A (50 μg per larva) was injected into MRSA-infected silkworm larvae, larvae all survived to at least day 3 ( Figure 3C ), while untreated larvae became black and died ( Figure 3A) . Nosokomycin A alone (50 μg per larva) had no toxic effect on uninfected larvae at least for 3 days ( Figure  3B ), indicating that the compound showed no toxicity to silkworm larvae. Nosokomycin B (50 μg per larva) also showed similar therapeutic efficacy for MRSA infected silkworm larvae (data not shown). Under the same conditions, vancomycin (50 μg per larva) showed the same therapeutic efficacy ( Figure 3D ).
Therapeutic efficacy of nosokomycin A in MRSAinfected mice
To confirm its in vivo efficacy, nosokomycin A was evaluated in an MRSA-infected mouse assay (7). When MRSA was intraperitoneally infected to mice, all the mice died on day 1 (next day) ( Figures 4A and 4B) ; however, intravenous administration of nosokomycin A (3.12-25 mg/kg, on day 0) to MRSA-infected mice resulted in the dose-dependent survival of mice from MRSA infection ( Figure 4A ). At 25 mg/kg, 75% mice could survive MRSA infection. Vancomycin also showed in vivo efficacy by both subcutaneous ( Figure  4B ) and intravenous (data not shown) administration to MRSA-infected mice; however, subcutaneous administration of nosokomycin A did not show efficacy even at 25 mg/kg dose (data not shown).
Discussion
In this study, in vitro and in vivo anti-MRSA activities of nosokomycins A to D were investigated. As reported previously, nosokomycins were discovered in the screening using the silkworm-MRSA infection assay (8, 9) . All nosokomycins showed potent activity against most Gram-positive pathogenic bacteria with analogous MIC values, and nosokomycins B and D also showed moderate activity against Gram-negative bacteria (Table  1) . From MIC data, nosokomycin B appeared to show the most potent anti-microbial activity among the four nosokomycins. From population analysis using 54 clinically isolated MRSA strains (Figure 2) , it became clear that nosokomycin B is the most potent, followed by nosokomycins A, D, and C. Thus, it was suggested that the presence of a glucose residue at R1 and an amino residue at R2 in the structure is important for potent anti-MRSA activity. Nosokomycins belong to the phosphoglycolipid moenomycin family. Moenomycin A possesses a glucose residue at R1 and a chromophoric cyclopentenone residue via an amide bond at R2 (Figure 1 ). To understand, in particular, the importance of the cyclopentenone residue, it will be intriguing to compare anti-MRSA activity between nosokomycin B and moenomycin A, although we could not obtain moenomycin A, because nosokomycin-producing Streptomyces cyslabdanicus K04-0144 strain did not produce moenomycins. However, it was reported that the anti-S. aureuse activity of moenomycin A lacking the cyclopentenone moiety decreased tenfold compared with that of moenomycin A (14) .
We applied the silkworm-MRSA infection assay to the primary screening method, and discovered nosokomycins from the culture broth of Streptomyces cyslabdanicus K04-0144 (8, 9) . This study demonstrated that nosokomycin A proved intravenously active in an in vivo MRSA-infected mouse model (Figure 4 ) (7). Unfortunately, nosokomycin A was inactive by subcutaneous administration in the mouse infection assay, while vancomycin proved active in both administration methods, which might have been due to drug permeability into the bloodstream. All results showed the usefulness of in vivo-mimic MRSA infection assay using silkworm larvae to discover anti-MRSA agents effective in in vivo using mammalian animals. We hope this methodology accelerates the discover of anti-infective agents, overcoming many problems such as gaps between in vitro and in vivo model, animal protection and so on.
